CTLA4 and neoplasm: As several checkpoint inhibitors (for example, antibodies blocking CTLA-4 or PD-1) are currently undergoing testing as a means to restore anti-tumor immune responses in human trials,18, 40 it is conceivable that the clinical potential of such combination strategies could be exploited in the near future.